StreetInsider.com News Articles

BioLife Solutions (BLFS)2600 contracts of September 40 puts trade

Wed, 26 Aug 2026 14:47:34 -0400

BioLife Solutions (NASDAQ: BLFS) 30-day option implied volatility is at 36; compared to its 52-week of 30 to 107 with a focus on 2600 contracts of September 40 puts.

Benchmark Downgrades BioLife Solutions (BLFS) to Hold

Mon, 10 Aug 2026 06:11:22 -0400

Benchmark analyst Robert Wasserman downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Hold.

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $34.66 yesterday.

Form 10-Q BIOLIFE SOLUTIONS INC For: Jun 30

Thu, 06 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260806/26884540.html

Form 10-Q BIOLIFE SOLUTIONS INC For: Jun 30

Thu, 06 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260806/26884540.html

Form 8-K BIOLIFE SOLUTIONS INC For: Aug 06

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883832.html

Form 8-K BIOLIFE SOLUTIONS INC For: Aug 06

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883832.html

BioLife Solutions (BLFS) Tops Q2 EPS by 88c

Thu, 06 Aug 2026 16:04:42 -0400

BioLife Solutions (NASDAQ: BLFS) reported Q2 EPS of $0.91, $0.88 better than the analyst estimate of $0.03. Revenue for the quarter came in at $28.5 million versus the consensus estimate of $27.51 million.

For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.

BioLife Solutions Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:03:00 -0400

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell

BioLife Solutions Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:03:00 -0400

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell

BioLife Solutions Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:03:00 -0400

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell

BioLife Solutions Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:03:00 -0400

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell

Form 425 BIOLIFE SOLUTIONS INC Filed by: REPLIGEN CORP

Tue, 04 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26860640.html

Form 425 BIOLIFE SOLUTIONS INC Filed by: REPLIGEN CORP

Tue, 04 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26860640.html

Form 8-K BIOLIFE SOLUTIONS INC For: Aug 03

Mon, 03 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26859308.html

Form 8-K BIOLIFE SOLUTIONS INC For: Aug 03

Mon, 03 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26859308.html

Stephens Downgrades BioLife Solutions (BLFS) to Equal Weight

Mon, 27 Jul 2026 07:48:10 -0400

Stephens analyst Hannah Helfey downgraded BioLife Solutions (NASDAQ: BLFS) from Overweight to Equal Weight.

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $29.98 yesterday.

Form 425 BIOLIFE SOLUTIONS INC Filed by: REPLIGEN CORP

Fri, 24 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260724/26809960.html

Form 425 BIOLIFE SOLUTIONS INC Filed by: REPLIGEN CORP

Fri, 24 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260724/26809960.html

Jefferies Downgrades BioLife Solutions (BLFS) to Hold

Thu, 23 Jul 2026 08:35:03 -0400

Jefferies analyst Matthew Stanton downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Hold with a price target of $31.00 (from $30.00).

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $31.15 yesterday.

Jefferies Downgrades BioLife Solutions (BLFS) to Hold

Thu, 23 Jul 2026 08:35:03 -0400

Jefferies analyst Matthew Stanton downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Hold with a price target of $31.00 (from $30.00).

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $31.15 yesterday.

H.C. Wainwright Downgrades BioLife Solutions (BLFS) to Neutral

Thu, 23 Jul 2026 06:08:48 -0400

H.C. Wainwright analyst Yi Chen downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Neutral with a price target of $31.00 (from $32.00).

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $31.15 yesterday.

H.C. Wainwright Downgrades BioLife Solutions (BLFS) to Neutral

Thu, 23 Jul 2026 06:08:48 -0400

H.C. Wainwright analyst Yi Chen downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Neutral with a price target of $31.00 (from $32.00).

For an analyst ratings summary and ratings history on BioLife Solutions click here. For more ratings news on BioLife Solutions click here.

Shares of BioLife Solutions closed at $31.15 yesterday.

TD Cowen Downgrades BioLife Solutions (BLFS) to Hold

Thu, 23 Jul 2026 01:04:57 -0400

TD Cowen analyst Brendan Smith downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Hold with a price target of $31.00 (from $33.00).

The analyst comments: “We are downgrading BioLife Solutions to Hold from Buy and lowering our price target to $31 (~11x our FY27 revenue estimates) from $33 following this morning's announcement confirming Repligen's plan to acquire the company for $31/share (~2:1 equity:cash transaction). We remain constructive on the underlying business, though the announced transaction largely captures the near-term value creation opportunity we saw in the standalone story and shifts the investment case toward deal completion rather than business execution.”

For an

TD Cowen Downgrades BioLife Solutions (BLFS) to Hold

Thu, 23 Jul 2026 01:04:57 -0400

TD Cowen analyst Brendan Smith downgraded BioLife Solutions (NASDAQ: BLFS) from Buy to Hold with a price target of $31.00 (from $33.00).

For an

Form 8-K BIOLIFE SOLUTIONS INC For: Jul 21

Wed, 22 Jul 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260722/26802694.html